(Reuters) -The U.S. on Wednesday authorized Pfizer Inc’s antiviral COVID-19 pill for at-risk people aged 12 and above, making it the first oral treatment and which can be taken at home, providing a potentially important tool in the fight against the fast-spreading Omicron variant.
Pfizer’s antiviral regimen, Paxlovid, was nearly 90% effective in preventing hospitalizations and deaths in patients at high risk of severe illness, according to data from the company’s clinical trial. Recent lab data suggests the drug retains its effectiveness against Omicron, Pfizer said.
Pfizer raised its 2022 production projections to 120 million courses of treatment from 80 million and said it was ready to start immediate delivery in the U.S. The treatment’s two-drug regimen includes a new medicine and a second older antiviral called ritonavir.
“Paxlovid’s approval is a major milestone that marks another step towards making COVID-19 a much more manageable infection,” said Amesh Adalja, a senior scholar at the Johns Hopkins Institute for Health Security.
“There are two key issues, however, that remain: It will be scarce in the coming weeks and its optimal use requires prompt diagnosis, which can be difficult with the continual testing problems that plague us,” Adalja added.
Pfizer has said it has 180,000 treatment courses ready to ship this year. The U.S. government’s contract for 10 million courses of the drug is priced at $530 per course.
The Food and Drug Administration’s decision to issue emergency authorization for the treatment comes as the U.S. combats a surge in COVID-19 cases driven by the Omicron variant, with President Joe Biden announcing plans for more federal vaccination and testing sites.
The Omicron variant, first identified in southern Africa and Hong Kong in November, has spread across the world and now constitutes over 70% of new coronavirus cases in the United States, according to data from the U.S. Centers for Disease Control and Prevention.
The FDA said it authorized Paxlovid for emergency use for the treatment of mild-to-moderate disease in adults and children 12 years and older, who are at high risk for progression to severe COVID-19.
The drug is available by prescription only and should be initiated as soon as possible after diagnosis of COVID-19 and within five days of symptom onset, the FDA said. The pills are meant to be taken every 12 hours for five days beginning shortly after the onset of symptoms.
While the clinical trials did not include patients under the age of 18, Pfizer said, the authorized adult dosing regimen is expected to result in comparable blood concentration levels of the drug in pediatric patients 12 and older weighing at least 40 kg (88.2 lbs).
The second drug, ritonavir, is known to have interactions with some other prescription medicines. Pfizer has said that should be manageable and suggested most patients would be able to lower the dose of their other medications while being treated for COVID-19.
Pfizer said it plans to file a new drug application with the FDA in 2022 for potential full regulatory approval. The European Union’s drug regulator last week said that EU countries can use Paxlovid early after diagnosis of an infector, although the its full review of the drug has not been completed.
Pfizer has agreed to allow generic manufacturers to supply versions of the treatment to 95 low- and middle-income countries through a licensing agreement with international public health group Medicines Patent Pool (MPP). The generic versions are expected later next year.
A rival pill from Merck & Co is under review by the FDA. The drug, molnupiravir, developed with Ridgeback Biotherapeutics, cut hospitalization and death risk by 30% in a trial.
Pfizer shares were up 2% at $60.18 in afternoon trading on Wednesday.
(Reporting by Dania Nadeem, Ankur Banerjee in Bengaluru and Carl O’Donnell in New York; Editing by Bill Berkrot, Nick Zieminski and Leslie Adler)
Comments